CompletedEUCTR 2005-004621-25
Is premorbid functioning a predictor of outcome in patients with early onset psychosis treated with Risperdal Consta?
This historical record does not confirm current site availability.
Historical research recordMultiple countriesSchizophrenia
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Belgium · Greece and 5 more locations
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 300
- Sponsor
- Janssen-Cilag Medical Affairs EMEA
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Belgium, Greece, Ireland, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2005-004621-25
- Official title
Show the full official title
Is premorbid functioning a predictor of outcome in patients with early onset psychosis treated with Risperdal Consta?
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Belgium · Greece · Ireland
4 more locations
- Italy
- Lithuania
- Netherlands
- Portugal
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Janssen-Cilag Medical Affairs EMEA.
Want to explore more studies?
Explore studiesRelated studies
A 12-WEEK, MULTICENTER, OPEN-LABEL EXTENSION STUDY IN SUBJECTS WITH SCHIZOPHRENIA
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...